Zentalis Pharmaceuticals, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Zentalis is a clinical-stage oncology biopharmaceutical company with no approved products or product-sales revenue.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / prior period |
|---|---|---|
| License revenue | $40.6 million | $0 |
| Research and development expense | $49.6 million | $48.6 million |
| General and administrative expense | $15.7 million | $16.4 million |
| Operating loss | $24.8 million | $65.0 million |
| Net income (loss) attributable to Zentalis | $10.1 million | $(63.2) million |
| Operating cash flow | $(52.0) million | $(49.3) million |
| Cash, cash equivalents and marketable securities | $489.0 million | $482.9 million at December 31, 2023 |
Q1 2024 net income was driven by the Immunome transaction and investment gains, not product sales: the company recognized $40.6 million of license revenue from licensing its preclinical ROR1 ADC and platform, and $34.9 million of investment and other income, including a $31.2 million unrealized fair-value gain on Immunome shares. The cash-flow statement included a $25.6 million non-cash license-revenue adjustment and a $31.2 million non-cash mark-to-market adjustment.
At March 31, 2024, total assets were $557.5 million, total liabilities $98.7 million, and stockholders’ equity $458.8 million. The company reported no indebtedness. Lease liabilities totaled $45.4 million, including $2.7 million current and $42.6 million long-term. Current assets were $503.8 million and current liabilities $54.8 million.
Material changes and unusual items
- Immunome paid $15.0 million in cash and issued shares valued at $25.6 million at transaction execution; Zentalis recorded $40.6 million of license revenue. The shares were reported at a March 31 fair value of $56.7 million and are included in marketable securities.
- Investment and other income increased to $34.9 million from $4.1 million, primarily due to the Immunome share revaluation and higher investment returns.
- Operating expenses were broadly stable year over year. R&D rose $1.0 million, including increased azenosertib program expense ($21.7 million versus $12.9 million); G&A fell $0.6 million.
- Cash used in operations increased to $52.0 million from $49.3 million despite reported net income. Cash and cash equivalents were $37.6 million; cash-flow resources also include marketable securities.
- Kalyra Pharmaceuticals was dissolved in January 2024 and deconsolidated; the filing says the financial impact was immaterial.
Outlook, management commentary and risks
- Management expects existing cash, cash equivalents and marketable securities at March 31, 2024 to fund operating expenses and capital expenditure requirements into mid-2026. The estimate depends on assumptions and could prove shorter; the company says it will need substantial additional capital to support operations and development.
- Management concluded there was no substantial doubt about the company’s ability to continue as a going concern for the year after issuance of the interim financial statements.
- Azenosertib is being evaluated alone and in combinations; the company targets its first NDA submission for a gynecologic malignancy in 2026. Planned disclosures include MAMMOTH and BEACON initial/topline data in the second half of 2024, DENALI topline data in the first half of 2025, and TETON topline data in the second half of 2025. ZN-d5 plus azenosertib AML trial initial data are expected in the second half of 2024.
- Key risks include clinical safety, efficacy and enrollment uncertainty; dependence on azenosertib and ZN-d5; reliance on third-party manufacturers and CROs, including manufacturing exposure in China; need for further financing and possible dilution; biomarker/diagnostic execution; competition; and intellectual-property, regulatory and reimbursement risks.
- The company reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls as of March 31, 2024. It reported no material changes in internal control over financial reporting during the quarter.
Investor verification points
- Confirm the Immunome share valuation, restrictions on selling more than 50% of the shares until six months after closing (subject to exceptions), and the effect of subsequent share-price changes on reported income and liquidity.
- Assess cash burn and the mid-2026 runway using operating cash use, planned trial spending, lease commitments and the market value and liquidity of the Immunome shares.
- Track clinical readouts and timelines, particularly 2024 azenosertib and ZN-d5 data, and the stated 2026 NDA target; these are forward-looking expectations, not assured outcomes.
- Review the potential availability and terms of future financing: $140.3 million remained under the ATM program at quarter-end, with no shares sold under it during Q1 2024.
- Distinguish recurring operating performance from the quarter’s one-time license revenue and unrealized investment gain when evaluating earnings and operating trends.